DURECT Corporation, a specialty pharmaceutical company, develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. It focuses on the development of products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, cardiovascular disease, and other chronic diseases. The company manufactures and sells ALZET osmotic pumps used in laboratory research; and a range of LACTEL standard and custom biodegradable polymers and excipients used as raw materials for the pharmaceutical and medical device clients. Its product pipeline includes REMOXY, an oral oxycodone gelatin capsule for chronic pain, which has received complete response letter from the U.S. Food and Drug Administration (FDA); POSIDUR, a Phase III clinical trial release formulation of bupivacaine for the treatment of post-surgical pain; ELADUR, a Phase II transdermal bupivacaine patch intended to provide delivery of bupivacaine; and TRANSDUR, a Phase II transdermal sufentanil patch intended to provide delivery of sufentanil. The company's products pipeline also comprises ORADUR-based opioids, including hydrocodone and hydromorphone for the treatment of pain, which are in Phase I clinical trial; oxymorphone, an ORADUR-based opioid for which IND has been accepted by the FDA; ORADUR-ADHD, a drug candidate in Phase I clinical trial for the treatment of attention deficit hyperactivity disorder; and Relday, an injectable risperidone product in Phase I clinical trial used to treat the symptoms of schizophrenia and bipolar I disorder. It is also involved in developing various biologics programs/research programs in other therapeutic categories. DURECT Corporation has strategic agreements with Hospira, Inc., Nycomed Danmark ApS; Pain Therapeutics, Inc.; Zogenix, Inc.; and Pfizer Inc. The company was founded in 1998 and is headquartered in Cupertino, California.